Simtuzumab

Synonyms: 辛妥珠单抗; AB 0024; GS 6624
Simtuzumab (AB 0024; GS 6624) 是一种靶向赖氨酰氧化酶样蛋白 2 (LOXL2) 的单克隆抗体,它以非竞争性方式阻断胶原交联、降低 LOXL2 蛋白表达并减轻细胞外基质改变,从而减轻心肌纤维化并预防心功能障碍,同时下调 Myh7 和 Nppa 基因表达、降低收缩异质性并减少 COL1A1 沉积,可用于研究 LMNA 突变诱导的扩张型心肌病、特发性肺纤维化以及原发性硬化性胆管炎。
产品编号: MS-C16663 纯度: ≥99.0% CAS No.: 1318075-13-6
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
询价
50mg
询价
询价

产品描述

Simtuzumab (AB 0024; GS 6624) 是一种靶向赖氨酰氧化酶样蛋白 2 (LOXL2) 的单克隆抗体,它以非竞争性方式阻断胶原交联、降低 LOXL2 蛋白表达并减轻细胞外基质改变,从而减轻心肌纤维化并预防心功能障碍,同时下调 Myh7 和 Nppa 基因表达、降低收缩异质性并减少 COL1A1 沉积,可用于研究 LMNA 突变诱导的扩张型心肌病、特发性肺纤维化以及原发性硬化性胆管炎。

生物实验数据

生物活性 Simtuzumab (AB 0024; GS 6624) is a monoclonal antibody targeting lysyl oxidase-like protein 2 (LOXL2) that non-competitively blocks collagen cross-linking, reduces LOXL2 protein expression, and alleviates extracellular matrix alterations, thereby attenuating myocardial fibrosis and preventing cardiac dysfunction while downregulating Myh7 and Nppa gene expression, reducing contractile heterogeneity, and decreasing COL1A1 deposition, and it can be used for the study of LMNA mutation-induced dilated cardiomyopathy, idiopathic pulmonary fibrosis, and primary sclerosing cholangitis.
IC50 & Target

LOXL2

体外研究
(In Vitro)

Simtuzumab (1 µM;15 天) 可降低 LMNAH222P 人诱导多能干细胞来源心肌细胞 (hiPSC-CMs) 的收缩异质性、收缩时间、舒张时间以及 COL1A1 沉积面积,且不改变收缩幅度。
Simtuzumab (1-50 μg/mL;72 小时) 在 50 μg/mL 的条件下可增强特发性肺纤维化 (IPF) 原代人肺成纤维细胞的肌成纤维细胞分化,在 IL-13 刺激时该作用尤为显著;且在无额外刺激的相同剂量下,可诱导正常原代人肺成纤维细胞发生轻度分化。
Simtuzumab (50 μg/mL;7 天) 即使存在促纤维化刺激,也不会减少或改变原代正常或特发性肺纤维化 (IPF) 人肺成纤维细胞中Ⅰ型胶原蛋白的合成。
Simtuzumab (50 μg/mL;96 小时) 可在划痕伤口实验中增强原代正常及特发性肺纤维化 (IPF) 人肺成纤维细胞的侵袭性迁移。
Simtuzumab (50 μg/mL;26 天) 可促进来自正常与特发性肺纤维化 (IPF) 人肺组织块混合原代成纤维细胞的生长,并上调这些培养物中纤维化相关基因的表达。
Simtuzumab (50 μg/mL;24 小时) 可提高正常人肺样本中 SSEA4+富集的间充质祖细胞内 αSMA 和 Collagen 3 的转录本表达水平。
Simtuzumab (50 μg/mL;10 天) 可提高正常及特发性肺纤维化 (IPF) 人肺组织外植体来源的混合原代细胞中 LOXL2 和 PDGFRA 的转录本表达,并诱导其发生间质样形态学改变。
Simtuzumab 可抑制人源 LOXL2 的酶活性,阻断成纤维细胞活化,并在体外实验中减少 LOXL2 介导的细胞外基质修饰。

ELISA Assay

Cell Line: primary IPF human lung fibroblasts
Concentration: 1 μg/mL; 10 μg/mL; 50 μg/mL
Incubation Time: 72 h
Result: Enhanced myofibroblast differentiation at 50 μg/mL with IL-13 stimulation.
Induced mild differentiation in primary normal human lung fibroblasts at 50 μg/mL without additional stimuli.

ELISA Assay

Cell Line: primary normal and IPF human lung fibroblasts
Concentration: 50 μg/mL
Incubation Time: 7 days
Result: Did not reduce or alter collagen 1 synthesis.

Cell Migration Assay

Cell Line: primary normal and IPF human lung fibroblasts
Concentration: 50 μg/mL
Incubation Time: 96 h
Result: Increased the invasive migration.
体内研究
(In Vivo)

Simtuzumab (5 mg/kg;腹腔注射;每周 3 次;持续 1 个月) 可在 LMNA 相关扩张型心肌病小鼠模型中保留左心室射血分数和缩短分数、减少心肌纤维化并稳定左心室扩张。
Simtuzumab (15 mg/kg;静脉注射;每周 2 次;预防性给药 35 天,治疗性给药 28 天) 在特发性肺纤维化的人源化 NSG 小鼠模型中无法调节肺纤维化,与 IgG 对照组相比,关键纤维化终点无显著差异;不过,与未处理组或仅细胞组相比,它会升高肺羟脯氨酸水平,且在预防性给药方案中会增加 SCA1+间充质祖细胞。

Animal Model: LmnaH222P/H222P (male, 4 months old at treatment initiation, homozygous genetic model with established cardiac disease phenotype)
Dosage: 5 mg/kg
Administration: i.p.; 3× weekly; 1 month
Result: Reduced Loxl2 protein expression in mouse hearts.
Decreased myocardial fibrosis as shown by Sirius red staining.
Stabilized left ventricular end-diastolic diameter (LVEDd) at ~3.5 mm from 4 to 5 months, compared to an increase from 3.5 mm to 4.1 mm in untreated mice.
Preserved ejection fraction (EF) from 70.9% at 4 months to 67.1% at 5 months, compared to a decline from 67.8% to 50.0% in untreated mice.
Maintained fractional shortening from 39.6% at 4 months to 36.5% at 5 months, compared to a decline from 37.2% to 25.1% in untreated mice.
Lowered mRNA expression of cardiac stress markers Myh7 and Nppa in mouse hearts.
Animal Model: NOD Cg-PrkdcSCID IL2rgTm1wil Szi (NSG) (6- to 8-week-old, female, pathogen-free, humanized model induced by intravenous injection of ~1×106 IPF lung cells)
Dosage: 15 mg/kg
Administration: i.v.; twice a week; 35 days (preventative); 28 days (therapeutic)
Result: Significantly increased lung hydroxyproline levels compared to mice that received IPF cells alone in the preventative treatment group, but showed no difference compared to IgG-treated mice.
Significantly increased total lung hydroxyproline levels compared to naive mice in the therapeutic treatment group, but showed no difference compared to IgG-treated mice.
Significantly increased SCA1+ mesenchymal progenitors in bronchoalveolar lavage fluid compared to IgG-treated mice at day 35 of the preventative regimen.
Showed no significant differences compared to IgG-treated groups in fibrosis-related lung transcripts, αSMA+ cell counts, collagen intensity, or histological appearance at day 63.
Clinical Trial
NCT NumberSponsorConditionStart DatePhase
NCT01369498Gilead Sciences
Myelofibrosis
2011-06-30PHASE2
NCT01472198Gilead Sciences
Pancreatic Cancer
2011-11PHASE2
NCT01707472Gilead Sciences|National Institute of Allergy and Infectious Diseases (NIAID)
Liver Fibrosis|Hepatitis C|HIV|HIV+HCV Co-infection
2012-10-04PHASE2
性状 液体
颜色 Colorless to light yellow

化学信息

CAS No. 1318075-13-6
别名 辛妥珠单抗; AB 0024; GS 6624

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Shipping with dry ice.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础